Baiyunshan Pharmaceuticals (00874.HK) (600332.SH) announced that its subsidiary, Baiyunshan Pharmaceutical General Factory, has received approval from the National Medical Products Administration for the issuance of a "Drug Registration Certificate" for Tadalafil tablets. The drug is mainly used to treat male erectile dysfunction. The original research and development was done by Eli Lilly and Co in the USA and was approved in the EU and USA in November 2002 and November 2003, respectively, and was approved for listing in China in December 2004.
白雲山(00874.HK)分公司治療男性勃起障礙藥獲註冊證書
Baiyunshan (00874.HK) subsidiary's treatment for male erectile dysfunction medicine obtains registration certificate.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.